Page last updated: 2024-10-25

ciglitazone and Airway Hyper-Responsiveness

ciglitazone has been researched along with Airway Hyper-Responsiveness in 3 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rhee, CK1
Lee, SY1
Kang, JY1
Kim, SJ1
Kwon, SS1
Kim, YK1
Park, SH1
Woerly, G1
Honda, K1
Loyens, M1
Papin, JP1
Auwerx, J1
Staels, B1
Capron, M1
Dombrowicz, D1
Ward, JE1
Fernandes, DJ1
Taylor, CC1
Bonacci, JV1
Quan, L1
Stewart, AG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874]Phase 216 participants (Actual)Interventional2008-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Exhaled Nitric Oxide in Parts Per Billion (Ppb), Parts Per Billion

Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks

Interventionparts per billion (Mean)
Baseline12 weeks
Rosiglitazone4841

Forced Expiratory Volume in 1 Second (FEV1)

FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks

InterventionLiters (Mean)
BaselineWeek 12
Rosiglitazone2.953.04

Forced Expiratory Volume in One Second (FEV1) Percent Predicted

Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks

Interventionpercent predicted (Mean)
BaselineWeek 12
Rosiglitazone8285

Methacholine Responsiveness as Assessed by PC20,

PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks

Interventionmg/mL (Mean)
BaselineWeek 12
Rosiglitazone3.278.71

Other Studies

3 other studies available for ciglitazone and Airway Hyper-Responsiveness

ArticleYear
Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma.
    International archives of allergy and immunology, 2009, Volume: 148, Issue:4

    Topics: Administration, Intranasal; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchial Provocation T

2009
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.
    The Journal of experimental medicine, 2003, Aug-04, Volume: 198, Issue:3

    Topics: Anilides; Animals; Asthma; Chemotaxis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation

2003
The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
    Pulmonary pharmacology & therapeutics, 2006, Volume: 19, Issue:1

    Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Bronchoconstrictor Agents; Disease Models, Animal;

2006